| Identification | Back Directory | [Name]
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one | [CAS]
247257-48-3 | [Synonyms]
Kanarb
BR-A-657
Fimasartan
Unii-p58222188p
KANARB; BR-A-657
Fimasartan(BR-A-657)
FiMasartan USP/EP/BP
Fimasartan Impurity H
2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrim
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one
2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide
5-PyriMidineethanethioaMide,2-butyl-1,6-dihydro-N,N,4-triMethyl-6-oxo-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-
2-(2-butyl-4-methyl-6-((2'-(1-trityl-1H-tetrazol-5-yl)-[ 1,1'-biphenyl]-4-yl)methoxy)pyrimidin-5-yl)-N,N- dimethylacetamide
2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one USP/EP/BP
2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
2-(2-butyl-4-Methyl-6-oxo-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-1,6-dihydropyriMidin-5-yl)-N,N-diMethylethanethioaMide
2-(2-butyl-4-Methyl-6-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methoxy)pyriMidin-5-yl)-N,N-diMethylacetaMide-yl)-N,N-diMethylacetaMide | [EINECS(EC#)]
207-981-6 | [Molecular Formula]
C27H31N7OS | [MDL Number]
MFCD24369685 | [MOL File]
247257-48-3.mol | [Molecular Weight]
501.65 |
| Chemical Properties | Back Directory | [Melting point ]
>155°C (dec.) | [Boiling point ]
693.0±65.0 °C(Predicted) | [density ]
1.25 | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.16±0.10(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Description]
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals. | [Uses]
Fimasartan is a new angiotensin II receptor blocker antagonist and also functions as an antihypertensive agent. | [Definition]
ChEBI: Fimasartan is a member of biphenyls. | [Biological Activity]
Fimasartan (Kanarb) is a non-peptide angiotensin II receptor antagonist (ARB) with noncompetitive, insurmountable binding with the AT1 receptor. It is used for the treatment of hypertension and heart failure. | [Mechanism of action]
Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect. | [storage]
Store at -20°C |
|
|